Insight Molecular Diagnostics Inc. (IMDX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $70.03M
Last updated: Nov 17, 2026 at 11:06 AM ET
Insight Molecular Diagnostics Inc. (IMDX) Stock Forecast
Analysts expect Insight Molecular Diagnostics (IMDX) to earn -$0.93 per share in the fiscal year ending Dec 31, 2026, on revenue of $966200. Of 5 analysts, 3 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.20, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 60% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 2 | 40.0% |
| Hold | 2 | 40.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 589.3%.
- Fiscal year ending Dec 31, 2026
- -$0.93
- EPS consensus, revenue $966200
- Fiscal year ending Dec 31, 2027
- -$0.80
- EPS consensus, revenue $6.66M
- Next report
- Mar 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.93 | -$0.93 to -$0.92 | 2 | $966200 | $400000 to $1.70M | 5 |
| Dec 31, 2027 | -$0.80 | -$0.84 to -$0.76 | 2 | $6.66M | $1.01M to $11.90M | 5 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.24 to -$0.23 | 7 | $477156 | $98000 to $1.16M | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.85.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.93 | -$0.93 | -$0.93 | -$0.93 | -$0.85 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.80 | -$0.80 | -$0.80 | -$0.84 | -$0.78 | N/A |
Frequently Asked Questions About IMDX
What is the IMDX stock forecast?
Consensus analyst estimates put Insight Molecular Diagnostics's EPS at -$0.93 for the fiscal year ending Dec 31, 2026, on revenue of $966200. The consensus rating from 5 analysts is Buy.
How do analysts rate IMDX stock?
Of 5 analysts covering Insight Molecular Diagnostics, 1 rates it Strong Buy, 2 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IMDX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.93, with estimates from -$0.93 to -$0.92 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.80, with estimates from -$0.84 to -$0.76 from 2 analysts.
What revenue do analysts expect from Insight Molecular Diagnostics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $966200, with estimates from $400000 to $1.70M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.66M, with estimates from $1.01M to $11.90M.
How many analysts cover IMDX?
5 analysts rate Insight Molecular Diagnostics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IMDX pages: Overview, Earnings, Forecast, Financials, Competitors